Induction of Selenoprotein P mRNA during Hepatitis C Virus Infection Inhibits RIG-I-Mediated Antiviral Immunity

Area of Science:

• Hepatology
• Immunology
• Endocrinology

Background:

• Hepatitis C virus (HCV) infection is associated with an increased risk of type 2 diabetes.
• Liver abnormalities in HCV infection may contribute to this metabolic complication.

Purpose of the Study:

• To investigate the role of selenoprotein P (SeP) in the link between HCV infection, insulin resistance, and innate immunity.
• To explore SeP as a potential biomarker for HCV treatment outcomes.

Main Methods:

• Quantification of hepatic SEPP1 mRNA and serum SeP levels in HCV-infected patients.
• In vitro studies assessing SeP's interaction with RIG-I and its effect on interferon responses.
• Correlation analysis of SeP levels with type 2 diabetes risk and direct-acting antiviral treatment failure.

Main Results:

• HCV infection upregulates hepatic SEPP1 mRNA and serum SeP levels.
• SeP directly inhibits retinoic-acid-inducible gene I (RIG-I), dampening type I interferon responses.
• SeP knockdown enhances interferon-stimulated genes and reduces HCV replication.
• High serum SeP levels correlate with treatment failure in HCV patients receiving direct-acting antivirals.

Conclusions:

• Selanoprotein P (SeP) is a key mediator linking HCV infection to insulin resistance and immune tolerance.
• Upregulated SeP may contribute to the increased incidence of type 2 diabetes in HCV patients.
• Serum SeP levels serve as a predictive biomarker for direct-acting antiviral therapy response in HCV.